SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals,
Inc. (Nasdaq: HEPH), a leader in the development of a new class of small
molecule compounds based on endogenous adrenal steroid hormones, today
announced the board of directors has appointed James M. Frincke Ph.D. as
President and CEO of Hollis-Eden Pharmaceuticals, Inc. Dr. Frincke was also
elected to the company's board of directors.
Dr. Frincke joined Hollis-Eden as Vice President, Research and Development
in 1997, was promoted to Executive Vice President in 1999, and to Chief
Scientific Officer in 2001. Dr. Frincke joined Hollis-Eden from Prolinx, Inc.,
where he served as Vice President, Therapeutics Research and Development from
1995 to 1997. During his 28 years in the biotechnology industry, Dr. Frincke
has managed major development programs including drugs, biologicals, and
cellular and gene therapy products aimed at the treatment of cancer,
infectious diseases and organ transplantation. Since joining the biotechnology
industry, Dr. Frincke has held vice president, research and development
positions in top tier biotechnology companies including Hybritech/Eli Lilly
and SyStemix Inc. (acquired by Novartis). In various capacities, he has been
responsible for all aspects of pharmaceutical development including early
stage research programs, product evaluation, pharmacology, manufacturing, and
the management of regulatory and clinical matters for lead product
opportunities. Dr. Frincke has authored or co-authored more than 100
scientific articles, abstracts and regulatory filings. Dr. Frincke received
his B.S. in Chemistry and his Ph.D. in Chemistry from the University of
California, Davis. Dr. Frincke completed his postdoctoral work at the
University of California, San Diego. Dr. Frincke has been with Hollis-Eden
for more than 11 years.
About Hollis-Eden Pharmaceuticals, Inc.
Hollis-Eden Pharmaceuticals, Inc. is developing a new series of small
molecule compounds that are metabolites or synthetic analogs of endogenous
hormones derived by the adrenal glands from the body's most abundant
circulating adrenal steroid. The Company's clinical drug development
candidates include TRIOLEX(R) (HE3286), a next-generation compound currently
in clinical trials for the treatment of type 2 diabetes, ulcerative colitis
and rheumatoid arthritis, and APOPTONE(R) (HE3235), a next-generation compound
in a clinical trial for the treatment of late-stage prostate cancer. For more
information on Hollis-Eden, visit the Company's website at www.holliseden.com.
This press release contains forward-looking statements within the meaning
of the federal securities laws concerning, among other things, the potential
and prospects of the Company's drug discovery program and its drug candidates.
Any statement included in this press release that are not a description of
historical facts are forward-looking statements that involve risks,
uncertainties, assumptions and other factors which, if they do not materialize
or prove correct, could cause the Company's actual results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. Such statements are subject to certain risks and
uncertainties inherent in the Company's business, including, but not limited
to: the ability to complete preclinical and clinical trials successfully and
within specified timelines, if at all; the ability to obtain regulatory
approval for TRIOLEX(R) (HE3286), APOPTONE(R) (HE3235) or any other
investigational drug candidate; the Company's future capital needs; the
Company's ability to obtain additional funding; the ability of the Company to
protect its intellectual property rights and to not infringe the intellectual
property rights of others; the development of competitive products by other
companies; and other risks detailed from time to time in the Company's filings
with the Securities and Exchange Commission. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. Except as
required by law, the Company undertakes no obligation to update or revise the
information contained in this press release as a result of new information,
future events or circumstances arising after the date of this press release.
SOURCE Hollis-Eden Pharmaceuticals, Inc.
-0- 06/15/2009
CONTACT:
Bob Weber, Interim CFO, Hollis-Eden Pharmaceuticals, Inc.,
+1-858-587-9333
Web Site: http://www.holliseden.com
